RU2000112547A - COMPOSITIONS AND METHODS OF SYSTEM DELIVERY OF ORAL VACCINES AND THERAPEUTIC AGENTS - Google Patents

COMPOSITIONS AND METHODS OF SYSTEM DELIVERY OF ORAL VACCINES AND THERAPEUTIC AGENTS

Info

Publication number
RU2000112547A
RU2000112547A RU2000112547/14A RU2000112547A RU2000112547A RU 2000112547 A RU2000112547 A RU 2000112547A RU 2000112547/14 A RU2000112547/14 A RU 2000112547/14A RU 2000112547 A RU2000112547 A RU 2000112547A RU 2000112547 A RU2000112547 A RU 2000112547A
Authority
RU
Russia
Prior art keywords
botulinum toxin
compositions
methods
therapeutic agents
modified
Prior art date
Application number
RU2000112547/14A
Other languages
Russian (ru)
Other versions
RU2227042C2 (en
Inventor
Лэнс СИМПСОН
Никита КИЯТКИН
Эндрю МАКСИМОВИЧ
Original Assignee
Томас Джефферсон Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/954,302 external-priority patent/US6051239A/en
Application filed by Томас Джефферсон Юниверсити filed Critical Томас Джефферсон Юниверсити
Publication of RU2000112547A publication Critical patent/RU2000112547A/en
Application granted granted Critical
Publication of RU2227042C2 publication Critical patent/RU2227042C2/en

Links

Claims (6)

1. Модифицированный ботулинический токсин, содержащий ботулинический токсин, способный к транслокации из кишечника в общий кровоток, который изменен таким образом, что является нетоксичным.1. A modified botulinum toxin containing botulinum toxin capable of translocation from the intestine into the general bloodstream, which is modified in such a way that it is non-toxic. 2. Модифицированный ботулинический токсин по п. 1, дополнительно содержащий выбранный антиген. 2. The modified botulinum toxin according to claim 1, additionally containing the selected antigen. 3. Модифицированный ботулинический токсин по п. 1, дополнительно содержащий терапевтический агент. 3. The modified botulinum toxin according to claim 1, further comprising a therapeutic agent. 4. Пероральная вакцина против ботулизма, содержащая модифицированный ботулинический токсин по п. 1 и фармацевтически приемлемый носитель. 4. An oral botulism vaccine comprising the modified botulinum toxin according to claim 1 and a pharmaceutically acceptable carrier. 5. Пероральная вакцина против выбранного антигена, содержащая модифицированный ботулинический токсин по п. 2 и фармацевтически приемлемый носитель. 5. An oral vaccine against a selected antigen containing the modified botulinum toxin according to claim 2 and a pharmaceutically acceptable carrier. 6. Способ пероральной доставки терапевтического агента животному, включающий введение животному модифицированного ботулинического токсина по п. 3. 6. A method for oral delivery of a therapeutic agent to an animal, comprising administering to the animal a modified botulinum toxin according to claim 3.
RU2000112547/15A 1997-10-20 1998-10-16 Compositions amd methods for systemic delivery of oral vaccines and therapeutic agents RU2227042C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/954,302 1997-10-20
US08/954,302 US6051239A (en) 1997-10-20 1997-10-20 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents

Publications (2)

Publication Number Publication Date
RU2000112547A true RU2000112547A (en) 2002-05-20
RU2227042C2 RU2227042C2 (en) 2004-04-20

Family

ID=25495232

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000112547/15A RU2227042C2 (en) 1997-10-20 1998-10-16 Compositions amd methods for systemic delivery of oral vaccines and therapeutic agents

Country Status (16)

Country Link
US (1) US6051239A (en)
EP (1) EP1024827B1 (en)
JP (1) JP2001522783A (en)
KR (1) KR100594787B1 (en)
CN (1) CN1246038C (en)
AT (1) ATE355076T1 (en)
AU (1) AU756475B2 (en)
BR (1) BR9815255A (en)
CA (1) CA2306995A1 (en)
DE (1) DE69837209T2 (en)
EE (1) EE200000536A (en)
HU (1) HUP0101017A3 (en)
IL (1) IL135743A (en)
NZ (1) NZ504549A (en)
RU (1) RU2227042C2 (en)
WO (1) WO1999020306A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
DK1253932T3 (en) * 2000-02-08 2005-06-27 Allergan Inc Botulinum toxin drugs
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
AU2888702A (en) * 2000-11-06 2002-05-15 Us Army Med Res Mat Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
JP4707254B2 (en) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 Granular composition and method for producing the same
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
WO2004044161A2 (en) 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
NZ540425A (en) * 2002-12-20 2009-03-31 Botulinum Toxin Res Ass Inc Pharmaceutical botulinum toxin compositions
WO2004070016A2 (en) 2003-02-03 2004-08-19 Fraunhofer Usa Inc. System for expression of genes in plants
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
EP1769068B1 (en) * 2004-02-20 2014-12-31 iBio, Inc. Systems and methods for clonal expression in plants
US7306807B2 (en) * 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
CA2588758C (en) * 2004-11-22 2017-01-03 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
KR20110126726A (en) 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 Vaccines and methods to treat canine influenza
EP1931379B1 (en) 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
CA2681183A1 (en) * 2007-05-30 2008-12-11 Wyeth Raccoon poxvirus expressing genes of feline antigens
WO2009042165A2 (en) * 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
WO2014117148A1 (en) 2013-01-28 2014-07-31 New York University Treatment methods using atoxic neurotoxin derivatives
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
KR20200100755A (en) 2017-12-20 2020-08-26 알레간 인코포레이티드 Botulinum toxin cell binding domain polypeptide and method of use for skin regeneration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
JP3523879B2 (en) * 1994-05-31 2004-04-26 アレルガン インコーポレイテッド Modification of Clostridium toxin for transport proteins
ATE366312T1 (en) * 1994-10-24 2007-07-15 Ophidian Pharm Inc VACCINE AND ANTITOXINS FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE DISEASES
WO1996040229A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Vaccines synthesized by transgenic plants

Similar Documents

Publication Publication Date Title
RU2000112547A (en) COMPOSITIONS AND METHODS OF SYSTEM DELIVERY OF ORAL VACCINES AND THERAPEUTIC AGENTS
RU2227042C2 (en) Compositions amd methods for systemic delivery of oral vaccines and therapeutic agents
BR9106114A (en) METHOD FOR TREATING OR PREVENTING AN AUTOIMMUNE DISEASE (AD) AND PHARMACEUTICAL FORMULATION
PT815235E (en) VACCINES FOR FEAST
RU95109905A (en) Liquid, semisolid, solid, gel-like or paste-like compositions and a method of mouth cavity disease treatment
EP1033998A4 (en) Method of suppressing beta-amyloid-related changes in alzheimer's disease
IL141623A0 (en) Method of dna vaccination
NZ504894A (en) Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
DE69521880T2 (en) ORAL ADMINISTRATION SYSTEM OF CHEMICALLY MODIFIED PROTEINS G-CSF
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
AU7814498A (en) Multivalent (in ovo) avian vaccine
BG106221A (en) Morphine-containing intranasal pharmaceutical preparations and methods for their administration
BR9914631A (en) Tolerance-inducing oral immunological composition for disease prevention and / or treatment and method for disease prevention and / or treatment
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
ZA96835B (en) Pharmaceutical non inorganic saline solutions for endonasal administration
BR9802537A (en) Method to anesthetize a human patient before single-dose surgery and pharmaceutical system for administration
JP2680809B2 (en) Compositions and methods for treating animals
WO1999018998A3 (en) Delivery system
GB2313782B (en) Method and vaccine for prevention of over-production of acid in the rumen or gut of animals
ATE12649T1 (en) OPTICALLY ACTIVE DIPEPTIDE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, METHOD OF PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
MX9604539A (en) Modified amino acids for drug delivery.
RU2001124669A (en) Method for the prevention of calf paratyphoid
RU2000132659A (en) METHOD FOR ANIMAL ENZYMOSTERILIZATION OF ANIMALS
FR2698271B1 (en) Bovine leukemia virus vaccine, new immunogenic peptide and vaccination kit.
UA30011A (en) The method of prophylaxis of acute stress gastrointestinal tract lesions after the cavitary surgery